南予医学雑誌　第18巻

39/91

南予医誌　Vol.18　No. １　2017－38－An increase in the number of cases of luminal HER2-positive breast cancer detected by HER2 gene amplification using fluorescence in-situ hybridizationAbstract　Human epidermal growth factor receptor ２（HER２）is overexpressed in some patients with breast cancer. HER２ status is important in terms of prescription of the molecularly targeted drug trastuzumab. The American Society of Clinical Oncology （ASCO）/College of American Pathologists（CAP）guidelines for HER2 testing in breast cancer patients were updated in 2013；cases with immunohistochemical scores ２＋ on fluorescence in situ hybridization（FISH）are increasing in number. Accordingly, cases of HER２-positive breast cancer are also increasing in number, but most are luminal in nature with a low risk of recurrence. Therefore, it is necessary to discuss the use of trastuzumab with all such patients and decide with them whether to use the drug. （Nan-yo Med J 2017; 18: 32-38.）keyword；luminal HER２-positive breast cancerMiku NAKAGAWA1), Kenzo OKADA1), Gen KANESADA1), Naoki MUKAI1), Yusuke NISHI1), Katsuhiro TOMOFUJI1), Naoki ISHIDA1), Hajime SATO1), Yoshinori IMAI1), Taro NAKAMURA1), Kenji NEZU1), Jota WATANABE1), Toshihiko SAKAO1), Shoichi MATSUKAGE2), Mamoru NAKANISHI2),Shinsuke KAJIWARA1)1)Department of Surgery2)Department of pathology Uwajima City Hospital Goten-machi, Uwajima, Ehime 798-8510, Japan